This editorial provides an insight into the advancing field of microsampling as a tool to monitor critically ill patients in the clinic, highlighting the need for further development to ensure patients receive the highest quality of care.
In this interview, Laura Mercolini (University of Bologna) discusses the advantages and disadvantages of using volumetric absorptive microsampling (VAMS) as a bioanalytical tool, touching upon her recent paper on the same topic.
In this interview, Stephane Moreau (Shimadzu Europa) introduces the new Q-TOF LCMS-9030 instrument among other technologies available for automation and microsamping.
Researchers at the Brigham Young University (London, UK) have developed a non-invasive, nanoPOTS method for monitoring cancer by measuring the proteins in circulating tumor cells from the blood.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
Experts in microsampling share their knowledge and experience of what is required to complete a successful implementation, with insights for anyone struggling with a new and disruptive technology.
Volumetric absorptive microsampling and impact-assisted extraction: have we finally eliminated the hematocrit effect?
Altasciences’ experts share their most recent experience using Volumetric Absorptive Microsampling Mitra™ technology from product characterization to application development, highlighted with specific case studies.
In this Column, Stuart A. Kushon (Neoteryx; CA, USA) discusses what he feels is the key to successful implementation of microsampling.
Capillary microsampling in nonclinical safety assessment: practical sampling and bioanalysis from a CRO perspective
In this special report, the authors discuss the initial considerations before using capillary microsampling, study design and some practicalities of sample collection.
In this Methodology, the authors outline their use of capillary microsampling to collect smaller volumes of blood samples and the eliminated toxicokinetic satellite groups, during GLP toxicology studies.